Calculation of absorbed dose due to the 90Y-DOTATOC peptide receptor radionuclide therapy by MCNP5/X
| Autor: | Z Dragana Krstic, Z Marija Jeremic, D Milovan Matovic, R Dragoslav Nikezic, B Suzana Pantovic |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
peptide receptor radionuclide therapy
Peptide receptor dosimetry Chemistry business.industry 90Y-DOTATOC 3. Good health Monte Carlo simulations Nuclear Energy and Engineering Absorbed dose Radionuclide therapy lcsh:QC770-798 lcsh:Nuclear and particle physics. Atomic energy. Radioactivity Safety Risk Reliability and Quality Nuclear medicine business |
| Zdroj: | Nuclear Technology and Radiation Protection, Vol 33, Iss 4, Pp 380-385 (2018) |
| ISSN: | 1452-8185 1451-3994 |
| Popis: | Strong beta emitters, like 90Y, 177Lu labelled peptide, are used for treatment of neuroendocrine tumours where there is a good expression of somatostatin receptors. In this work, MCNP5/X computer software and ORNL human phantoms were used to calculate absorbed dose due to 90Y labelled DOTATOC in the peptide receptor radionuclide therapy. Tumour was considered as a sources of beta radiation and represented as a sphere with diameter of 1-4 cm and 5 cm in liver, pancreas, and lungs. Results are expressed as absorbed dose per unit of cumulated activity, S – value in units mGy·(MBq·s)–1. The far largest dose is in tumour itself, then in organ which contains the tumour. Doses in other organs, where the metastasis are the most frequent, due to the bremsstrahlung radiation, are much smaller and could be neglected. The largest dose, 8.66·10–3 mGy·(MBq·s)–1 was obtained for tumour with size of 3 cm. [Project of the Serbian Ministry of Education, Science and Technological Development, Grant no. 171021] |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|